Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

Interim Data From Peregrine's Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms
Kaplan-Meier overall survival Click here for high-resolution version

TUSTIN, CA--(Marketwire - Sep 7, 2012) -

  • Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium

  • Data Show Statistically Significant Improvement in Overall Survival for Patients Receiving Bavituximab Plus Docetaxel Versus Docetaxel Alone

  • Clinical Data Strongly Support Advancing Program into Phase III Clinical Development

  • Company to Host Conference Call on Monday, September 10, at 11:00 AM EDT

Peregrine Pharmaceuticals, Inc. ( NASDAQ : PPHM ), today announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm). The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.

    Treatment Arm
plus docetaxel
(1 mg/kg)
plus docetaxel
(3 mg/kg)
plus docetaxel
  Bavituximab (Pooled Data) plus docetaxel
Number of patients (per protocol population)   38   40   39  
Median Overall Surviva lHazard Ratio (p-value)  
5.6 months
  11.1 months
.512 (.0286)
  13.1 months
.539 (.0714)
  12.1 months
.524 (.0154)
Overall Response Ratep-value   7.9%
Progression Free Survival Hazard Ratio (p-value)   3.0 months
  4.2 months
.571 (.0794)
  4.5 months
.65 (.1921)
  4.2 months
.605 (.067)

"This study was a rigorous trial designed to minimize bias and we are encouraged that this trial yielded such positive results in the most important endpoint, overall survival. The positive overall response rates and progression free survival in both bavituximab-containing arms seen earlier in the study has now translated into a statistically significant extension in overall survival for patients, a result rarely achieved in phase II clinical trials." said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. "The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013." 

The trial enrolled 121 patients (117 evaluable per the study protocol) with second-line non-squamous NSCLC following one prior chemotherapy regimen at over 40 clinical centers. Patients were equally randomized to 1 of the 3 treatment arms, docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression. Approximately 50% of the patients were enrolled in the U.S. and 50% were enrolled internationally with equal distribution between all treatment groups.

"Robust data from this Phase II trial clearly demonstrate a significant benefit in overall survival with a good safety profile in patients receiving bavituximab plus docetaxel compared to those receiving docetaxel plus placebo," said Steven W. King, president and chief executive officer of Peregrine. "We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program. It is our goal to identify the optimal partner to assist with the design and logistics of a multinational Phase III pivotal trial."

The interim results from the study showed no significant safety differences between the three treatment arms as determined by the trial's independent data monitoring committee. Baseline characteristics were well balanced across all three treatment arms of the study, including performance (ECOG) status, age, gender, and race. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on blinded central radiology review.

"The median overall survival results from the Proof-of Concept study are truly outstanding and great news for patients. Statistically significant overall survival results at this stage of development are rare and have put us in an excellent position for advancing the program. Our attention is now turned to an end of phase II meeting by year end which will help us define the most efficient path forward to potential regulatory approval," said Robert Garnick, PhD, head of regulatory affairs at Peregrine. "A global Phase III trial designed very similarly to the robust design of this Phase II trial greatly increases bavituximab's likelihood of success."

Audio Webcast
In conjunction with Dr. Gerber's presentation in Chicago, Peregrine has posted an audio webcast and slide deck to Peregrine's website. The webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. This event will be pre-recorded. Access to the audio and corresponding slides can be found on Peregrine's website.

Conference Call
Peregrine will host a conference call and webcast to discuss these data and financial results for the first quarter fiscal year 2013 on Monday, September 10, 2012, at 11:00 AM ET (8:00 AM PT). To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Lung Cancer
According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in the U.S., with approximately 226,160 new cases and 160,340 deaths each year, representing approximately 28% of all cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Unfortunately, the five-year survival rate for NSCLC patients is only 1%.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company's PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but "flips" and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data together with the above reported data may not support registration filings with the U.S. Food and Drug Administration, the risk that overall survival data from the planned Phase III trial will not be consistent with the results from the randomized, double-blind, placebo-controlled Phase IIb trial, the risk that results from the other randomized Phase II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company's ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

  • Internal emails show McDonald’s turnaround is in trouble
    Business Insider

    Internal emails show McDonald’s turnaround is in trouble

    McDonald's turnaround is facing a major roadblock. The email was summarizing a September meeting between McDonald's executives and franchise leaders. McDonald's did not immediately respond to Business Insider's request for comment on the documents.

  • Apple 'leaks its own Macbook Pro laptop revamp'
    BBC News

    Apple 'leaks its own Macbook Pro laptop revamp'

    Apple appears to have leaked images of its next-generation laptop ahead of a press conference on Thursday. The photos support claims that the Macbook Pro will include a panel above its keyboard that replaces physical function keys with a thin display showing touch-sensitive text and graphics, and a fingerprint sensor. The images were discovered in an update to the MacOS operating system and first appeared on the MacRumors news site. Such "accidents" are not uncommon. In September, Apple tweeted and then deleted a video showing off the iPhone 7's new features ahead of its launch. Earlier in April, it referred to MacOS on its website two months before officially revealing it was rebranding the

  • Exclusive: WHO cancer agency asked experts to withhold weedkiller documents

    Exclusive: WHO cancer agency asked experts to withhold weedkiller documents

    By Kate Kelland LONDON (Reuters) - The World Health Organization's cancer agency - which is facing criticism over how it classifies carcinogens - advised academic experts on one of its review panels not to disclose documents they were asked to release under United States freedom of information laws. In a letter and an email seen by Reuters, officials from the International Agency for Research on Cancer (IARC) cautioned scientists who worked on a review in 2015 of the weedkiller glyphosate against releasing requested material. The review, published in March 2015, concluded glyphosate is "probably carcinogenic," putting IARC at odds with regulators around the world.

  • Everyone's Dream Boss, Joanna Gaines, Is Hiring
    Country Living

    Everyone's Dream Boss, Joanna Gaines, Is Hiring

    Looking for a career change that might involve farmhouse furniture, Christmas decorations, and plenty of bakery goodies? Magnolia Market, Joanna Gaines' furniture retailer and bakery located at the Silos in Waco, is hiring more staffers to join their teams for the holiday season, the brand announced on Instagram. If you have a knack for preparing tasty treats, for example, Magnolia Flour is looking for bakery sales associates and a baker.

  • Business

    Oil Prices Plunge After API Reports Significant Build To U.S. Crude Stocks

    American crude oil supplies surged upwards by 4.8 million barrels this week, almost completely offsetting last week’s 5.2-million-barrel draw, according to the American Petroleum Institute (API) report released on Tuesday. This week’s inventory build will likely press further down on oil prices, which were already trading down on the market’s increasing uneasiness over the OPEC drama, including Iraq’s OPEC rebellion, Russia’s vague and vacillating comments as to whether they’ll join in a freeze or a cut, and Venezuela’s pleas to get non-OPEC members to cut in proportion to the bloc’s to-be-determined limits. The West Texas Intermediate (WTI) price settled to three-week lows once the report went public Tuesday afternoon.

  • Caterpillar digs deeper into the abyss
    The Street

    Caterpillar digs deeper into the abyss

    Heavy equipment maker Caterpillar ( CAT) took the wrecking ball to its 2016 results, bringing down sentiment about the health of the world economy in the process. Caterpillar reported Tuesday a third-quarter profit of $283 million on sales of $9.2 billion, down from a revised $559 million profit on $11 billion in sales in the same quarter a year prior. For the full year, Caterpillar said it now expects sales of $39 billion compared to previous guidance of between $40 billion and $40.5 billion. The results continue a bad run for Caterpillar, which has attempted to weather weakness in the commodity and energy markets that has led to more than three years of flat to down month-over-month sales by slashing 20% of its global workforce and restructuring its operations.

  • 8 Things You Should Never Keep in Your Wallet

    8 Things You Should Never Keep in Your Wallet

    That overstuffed wallet of yours can’t be comfortable to sit on. It’s probably even too clunky to lug around in a purse, too. And with every new bank slip that bulges from the seams, your personal information is getting less and less safe. With just your name and Social Security number, identity thieves can open new credit accounts and make costly purchases in your name. If they can get their hands on (and doctor) a government-issued photo ID of yours, they can do even more damage, such as opening new bank accounts. These days, con artists are even profiting from tax-return fraud and health-care fraud, all with stolen IDs. We talked with consumer-protection advocates to identify the eight things

  • New Wells Fargo CEO to employees: 'We're sorry'
    Associated Press

    New Wells Fargo CEO to employees: 'We're sorry'

    Newly appointed Wells Fargo CEO Tim Sloan told employees Tuesday that he is "sorry for the pain" that the bank's employees have suffered as a result of the company's sales practices scandal. In the speech, Sloan acknowledged that the bank did not respond to the problems in its branches soon enough and that upper management dodged responsibility for the bad behavior and wrongly placed blame on branch employees. Wells Fargo is enveloped in the biggest scandal in its 164-year history, which earlier this month forced the abrupt retirement this month of its CEO, John Stumpf .

  • Politics
    Bloomberg Video

    Donald Trump Calls Out ‘Mr. Tough Guy’ Joe Biden

    Oct. 25 -- At a rally in Tallahassee, Florida, Donald Trump responds to Vice President Biden’s remark that he’d like to take the GOP nominee “behind the gym.”

  • Business
    Real Money

    Market Has Already Decided Election's Outcome

    I'm growing so tired of the recent trading-range action that I was hoping a bit too much that the negative reaction to Apple (AAPL) earnings and the weak action in small-caps might trigger some downside momentum. What happened instead is that the indices bounced right back and are barely unchanged. (Apple is part of TheStreet's Action Alerts PLUS portfolio.)  Breadth is still dicey at 2,600 gainers to 3,900 decliners and the small-caps indices are hanging on by their fingertips to support, but the S&P 500 is showing just a minor loss. It still isn't a very good setup for buying, but the story of this market has been -- and still is -- a lack of momentum in either direction. One question we were

  • UA
    Fox Business

    Under Armour Investors Punish CEO Kevin Plank

    Under Armour (NYSE:UA) CEO Kevin Plank is starting to sound like a broken record and investors are losing patience. The stock is seeing its biggest single-day loss in eight years, amid heavy volume, even as Plank downplayed concerns about the company’s declining growth rate on Tuesday. This doesn’t mean the demand for the Under Armour brand has disappeared, but it certainly hasn’t reappeared dollar-for-dollar in our distribution,” a seemingly-frustrated Plank said during post-earnings conference call.

  • 3 No-Brainer Stocks to Buy for Retirement

    3 No-Brainer Stocks to Buy for Retirement

    Retirement investing is not what it used to be. In the old days, one could just invest in the “safe” stocks to buy, in “blue chips,” in a nice ladder of bonds, and do just fine. Alas, the market has significantly changed. Much of this is due to the historically low interest rates we’ve had. The problem with the Federal Reserve’s attempt to goose the economy is that it killed bond yields, forcing retired investors further out onto the risk curve, making it difficult to find safe stocks to buy. That has pushed stock prices far higher than they should be, if one subscribes (as I do) to the Peter Lynch theory that a stock’s price should reflect its net income growth rate to be added to a list of

  • Cashing in small pensions 'more popular'
    BBC News

    Cashing in small pensions 'more popular'

    A rising number of retirees are cashing in their pension pots but the amount they typically withdraw has fallen, figures show. Savers can now cash in their pension pot from the age of 55. When the access was permitted for the first time last year, people were taking out sums averaging close to £20,000. The latest tax authority figures show typical withdrawals have fallen to about £10,000. This is evidence of retirees using the pension reforms to cash in smaller pension pots or taking part of their savings in cash while leaving the rest invested in a scheme. Previous research has suggested that the most popular use of the cash is for home improvements. Pension changes People aged 55 and over can

  • Best Vanguard Funds for Your Retirement Savings

    Best Vanguard Funds for Your Retirement Savings

    Vanguard is the biggest fund company in the land, with more than $3 trillion in assets. So chances are high that many retirement savers have access to Vanguard funds in their 401(k) plans. But size is no guarantee of good results. Thirty-four Vanguard funds appear on a list of the 105 most popular mutual funds in employer-sponsored retirement savings plans. No other fund company comes close. Not surprisingly, of the 34 most popular Vanguard funds in retirement plans, 15 are index funds. And nine more are target-date portfolios—those set-it-and-forget-it funds that shift over time to more conservative allocations as the fund nears its target year. The remaining 10 are actively managed. We didn’t

  • Anger still flares after judge OKs Volkswagen emissions deal
    Associated Press

    Anger still flares after judge OKs Volkswagen emissions deal

    A federal judge approved the largest auto-scandal settlement in U.S. history Tuesday, giving nearly a half-million Volkswagen owners and leaseholders the choice between selling their cars back or having them repaired so they don't cheat on emissions tests and spew excess pollution. U.S. District Judge Charles Breyer said the nearly $15 billion deal "adequately and fairly" compensates consumers and gets the polluting vehicles off the road as soon as possible. Under the agreement, owners can choose to have Volkswagen buy back their vehicle regardless of its condition for the full trade-in price on Sept. 18, 2015, when the scandal broke, or pay for repairs.

  • Target plays up value for the holiday season
    Associated Press

    Target plays up value for the holiday season

    From a Broadway-style marketing campaign to more exclusive toys, Target wants to lure shoppers during the final critical months of the year. Since becoming CEO two years ago, Brian Cornell has been trying to reinvigorate Target's cheap-chic status and focusing on categories like fashion, home furnishings and wellness items. Despite the contentious presidential race, Cornell believes shoppers are more upbeat about their financial situation, given low unemployment, less-expensive foods and cheaper gas.

  • News
    Bloomberg Video

    Trump Holds Narrow Lead in Florida: Bloomberg Poll

    Oct. 26 -- Republican presidential candidate Donald Trump holds a two percentage point advantage over Democrat Hillary Clinton in the battleground state of Florida, according to the latest Bloomberg politics poll. Bloomberg's Marty Schenker reports on "Bloomberg Surveillance."

  • Tesla Q3 earnings beat expectations, shares surge
    Yahoo Finance

    Tesla Q3 earnings beat expectations, shares surge

    Tesla (TSLA) shares rallied after the company reported earnings that were better than expected. During the quarter, Tesla delivered 24,821 vehicles, which is a bit higher than the 24,500 vehicles the company estimated earlier this month. This included 16,047 Model S and 8,774 Model X vehicles.

  • 5 Simple Mistakes That Could Ruin Your Retirement

    5 Simple Mistakes That Could Ruin Your Retirement

    You can make a lot of mistakes in your youth … and assuming none of them get you killed or put in prison, you can generally recover from them. Time is on your side. But the closer you get to retirement, the less room for error you have. You can make a lot of mistakes in your youth … and assuming none of them get you killed or put in prison, you can generally recover from them. Time is on your side. But the closer you get to retirement, the less room for error you have. As your nest egg gets larger, investing mistakes cost you a lot more. Think about it. If you lose 30% on a $10,000 portfolio, you’re out $3,000. That might be a single after-tax paycheck when you’re young. But imagine losing 30%

  • BA
    Associated Press

    Boeing has a banner 3Q and sees more of the same ahead

    Boeing's third-quarter profit rose 34 percent on lower taxes, and the company raised its forecast for 2016 earnings, revenue and airplane deliveries. The results beat Wall Street expectations, and Boeing shares rose in midday trading on Wednesday. CEO Dennis Muilenburg called the aircraft market "generally positive" with a "moderate" pace of sales orders.

  • Check for errors in your Social Security statements

    Check for errors in your Social Security statements

    Social Security can be a big part of your retirement income, so it helps to know if the federal government calculated your benefits correctly. A Social Security statement details your earnings history and estimated monthly retirement benefit. The Social Security Administration (SSA) mailed 47.9 million paper statements in the 2016 fiscal year, which ended September 2016.

  • 10 Worst States for Taxes on Your Retirement Nest Egg

    10 Worst States for Taxes on Your Retirement Nest Egg

    Retirees have special concerns when evaluating state tax policies. For instance, the mortgage might be paid off, but how bad are the property taxes—and how generous are the property-tax breaks for seniors? Are Social Security benefits taxed? What about other forms of retirement income—including IRAs and pensions? Does the state impose its own estate tax that might subtract from your legacy? The answers might just determine which side of the state border you’ll settle on in retirement. These 10 states impose the highest taxes on retirees, according to Kiplinger’s exclusive 2016 analysis of state taxes. Three of them treat Social Security benefits just like Uncle Sam does—taxing as much as 85%

  • News
    ABC News

    Ask Brianna: How Can I Get Help Paying for Graduate School?

    "Ask Brianna" is a Q&A column from NerdWallet for 20-somethings or anyone else starting out. I'm here to help you manage your money, find a job and pay off student loans — all the real-world stuff no one taught us how to do in college. Send your questions about postgrad life to Q: I want to get an advanced degree, but I'm not sure how to pay for it. How can I get financial aid as a graduate student? A: When I was unhappy at my job in my mid-20s, I daydreamed about going back to school the way some people long for a vacation to Costa Rica. I wanted to spar intellectually with professors instead of eating sad, solo lunches at my desk. I know this makes me a big nerd,

  • Business

    New York court orders Exxon, PwC to comply with NY AG subpoena

    Attorney General Eric Schneiderman's office moved the court on Oct. 14 to compel PwC to hand over certain documents after Exxon said it would not permit the auditor to do so. Schneiderman's office is investigating Exxon Mobil's accounting practices and why the oil major hadn't written down the value of its assets in the wake of a slump in oil prices, Reuters reported earlier.

  • Wells Fargo could see almost half its customers leave bank over scandal, management consulting firm cg42 says
    San Francisco Business Times

    Wells Fargo could see almost half its customers leave bank over scandal, management consulting firm cg42 says

    Steve Beck, founder and managing partner at cg42, told the San Francisco Business Times that the 14 percent of Wells Fargo customers planning to leave the bank would be far higher if not for the difficulty in moving to a new bank. No doubt Wells Fargo's rivals will be big winners if more customers exit Wells Fargo (NYSE: WFC). Credit unions, community banks and even Charles Schwab Bank (NYSE: SCHW) already appear to be benefitting from Wells Fargo's scandal. Cg42 says Bank of America (NYSE: BAC) and Chase Bank (NYSE: JPM) could also be big beneficiaries, given their national presence. On top of the 14 percent of existing customers that cg42 sees walking out the door at Wells Fargo, the consulting